Refine by
Immunotherapy Suppliers & Manufacturers
166 companies found
based inBuffalo, NEW YORK (USA)
POP Biotechnologies, Inc. (POP BIO) is dedicated to addressing critical medical challenges with advanced nanotechnologies. POP BIO’s key breakthrough, the porphyrin-phospholipid (PoP) platform, facilitates the creation of powerful light-targeted ...
SNAP liposomes contain synthetic MPLA, QS-21 and Cobalt porphyrin phospholipid (CoPoP). CoPoP enables liposomes to stably bind short MHC-I epitopes upon admixture. Better delivery of epitopes and adjuvants to immune cells in draining lymph nodes. ...
based inHuangpu District, CHINA
Moon (Guangzhou) Biotech Co., Ltd., with the title of National High-tech Enterprise, is an innovative biotechnology company focusing on the development and commercialization of microbial products and solutions. With a dedication to discover, ...
based inCharlottesville, VIRGINIA (USA)
LumaCyte is an advanced research and bioanalytics instrumentation company that produces label-free, single cell analysis instrumentation where the use of antibody or genetic labeling is not required for cellular analysis. This revolutionary ...
based inBoston, MASSACHUSETTS (USA)
We harness the natural power of the lymph nodes to generate enhanced immune responses against tumors. Our science is defining the future of immunotherapy, with the goal of giving patients who are battling cancer their best possible outcome. We’re ...
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most ...
based inSan Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
NEC OncoImmunity AS has developed an AI engine for its clinical projects, known as the NEC Immune Profiler, that predicts from next generation sequencing data true neoantigens for personalized cancer immunotherapy and cancer ...
based inVilligen, SWITZERLAND
leadXpro specializes in structure-based drug discovery for membrane proteins. leadXpro is a team of experts in membrane protein science. We have an integrated platform for membrane protein biochemistry, biophysics and structural biology, including ...
Using X-ray structure-based molecular design, leadXpro has discovered, optimised and patented two new series of selective antagonists of the A2B adenosine receptor. ...
based inMelbourne, AUSTRALIA
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care. ...
Revascor is a Phase 3 product candidate being developed as a treatment for both advanced and end-stage chronic heart failure ...
based inNew York, NEW YORK (USA)
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build ...
SL-701 is an immunotherapy designed to direct the immune system to attack targets present on certain malignancies including brain cancer. SL-701 comprises 3 short synthetic peptides that correspond to epitopes of targets including ...
based inNotting Hill, AUSTRALIA
Cartherics is developing its novel “off-the-shelf” (allogeneic) immune therapy products for the treatment of cancer based on immune killer cells. The company is developing large-scale manufacture of these CAR-iNK cells for application in human ...
based inHamburg, GERMANY
Indivumed GmbH was founded in 2002 by leading scientists with a drive to revolutionize cancer treatment through individualized therapy. As a physician-led, integrated global oncology company our experts leverage the world’s premier multi-omics ...
Cancer immunology, or “immuno-oncology,” is a growing field of research that aims to discover innovative cancer immunotherapies to treat and impede the progression of the disease. Understanding how cancer evades the ...
based inAnn Arbor, MICHIGAN (USA)
BlueWillow Biologics is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented nanoemulsion platform. The platform, originally discovered at the University of ...
Food allergy has become a significant health problem with increasing incidence and severity, particularly in children but continuing throughout adulthood. There is no cure for food allergy, and allergic reactions can be life threatening. According ...
based inSan Diego, CALIFORNIA (USA)
Decipher, a part of Veracyte, offers genomic tests for urologic cancers. Decipher Biosciences offers a portfolio of genomic tests, continues to build the GRID database of over 70,000 whole transcriptome profiles, and is partnering with ...
Nearly a decade of research and clinical testing has resulted in the accumulation of more than 85,000 whole transcriptome tumor profiles. Decipher GRID (for Research Use Only) is a proprietary artificial intelligence platform and database generating ...
based inLondon, UNITED KINGDOM
Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic ...
Using our proprietary computational vaccine design technology, we have developed a PolyPEPI preventive peptide vaccine against COVID-19 (SARS-CoV-2). The design of PolyPEPI-SCoV-2 exploits our knowledge on genetic heterogeneity of individuals ...
based inLachen, SWITZERLAND
We are the largest privately owned and independent plasma fractionator in the world. Family-owned since being established in 1983, Octapharma is a global healthcare company headquartered in Lachen, Switzerland. Our products are available in 118 ...
octagam® 5% (50 mg/ml), Human Normal Immunoglobulin. octagam® 10% (100 mg/ml), Human Normal Immunoglobulin. Liquid, ready-to-use intravenous immunoglobulin ...
based inParis, FRANCE
Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this ...
EO2401 is an innovative, off-the-shelf immunotherapy discovered by ...
based inRaleigh, NORTH CAROLINA (USA)
Kaio's strategy is to develop and in-license technologies and therapies that enable the body’s own immune system to work more efficiently. The goal is to improve clinical outcomes for patients, increase the number and efficacy of therapeutic options ...
Because Kaio’s IAHT elegantly induces necrosis while activating a systemic, tumor specific response, it can also serve as a platform for other immunotherapies seeking higher efficacies, broader markets and competitive ...
based inSacramento, CALIFORNIA (USA)
We are a next-generation biotechnology company creating an AI-powered platform for custom protein design. Our platform develops Novobinders: proprietary protein binders with diagnostic and therapeutic applications. AINovo Biotech works with select ...
based inPrinceton, NEW JERSEY (USA)
The drug discovery and development process is long and expensive with more failures than successes. At Certara, we anticipate and address your critical drug discovery and development risks and decisions using biosimulation, technology and services. ...
Biological medicines (“biologics” or “large molecule drugs”) now account for 30% of new drug approvals and up to 50% of the pharmaceutical industry’s pipeline. Biologics differ from small molecules because they are much ...
based inHergiswil, SWITZERLAND
BioLingus is a Swiss biotech company spearheading the development of oral (sublingual) delivery of peptides and proteins for chronic diseases and immuno-therapy via our innovative formulation technology. Our company focuses on the development of ...
Due to the fact that BioLingus drug administration is sublingual, and the use of a specific carrier molecule in the BioLingus formulation, the BioLingus technology is particularly effective for sublingual immuno ...